Ken Fisher Fisher Asset Management
Ken Fisher is the founder and executive chairman of Fisher Investments, a global money management firm overseeing billions of dollars in assets. He gained early recognition for pioneering the use of the price-to-sales ratio in stock analysis and wrote the long-running “Portfolio Strategy” column in Forbes. Over the years, Fisher has authored numerous books on investing and wealth management, many of which have become bestsellers.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$951M |
| 2 |
Advanced Micro Devices
AMD
|
+$589M |
| 3 |
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
|
+$418M |
| 4 |
Lam Research
LRCX
|
+$412M |
| 5 |
Microsoft
MSFT
|
+$207M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$1.24B |
| 2 |
Apple
AAPL
|
+$585M |
| 3 |
STMP
Stamps.com, Inc.
STMP
|
+$111M |
| 4 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
+$87.8M |
| 5 |
TSMC
TSM
|
+$70.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.05% |
| 2 | Financials | 11.79% |
| 3 | Healthcare | 10.9% |
| 4 | Consumer Discretionary | 10.36% |
| 5 | Communication Services | 8.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
501
Marriott International
MAR
$93.8B
| $1.52M | ﹤0.01% |
10,299
-65
| -0.6% | -$9.07K |
|
502
Novavax
NVAX
$1.27B
| $1.5M | ﹤0.01% |
7,241
+43
| +0.6% | +$9.48K |
|
503
Manitowoc
MTW
$510M
| $1.5M | ﹤0.01% |
69,870
+16,974
| +32% | +$393K |
|
|
SNV
504
DELISTED
Synovus
SNV
| $1.46M | ﹤0.01% |
33,264
+8,969
| +37% | +$379K |
|
505
iShares Global Financials ETF
IXG
$686M
| $1.44M | ﹤0.01% |
18,305
+694
| +4% | +$54.4K |
|
506
iShares US Pharmaceuticals ETF
IHE
$1.64B
| $1.42M | ﹤0.01% |
23,238
+1,395
| +6% | +$88.7K |
|
|
BZUN
507
Baozun
BZUN
$169M
| $1.41M | ﹤0.01% |
80,202
-42,153
| -34% | -$1.04M |
|
508
PNC Financial Services
PNC
$101B
| $1.4M | ﹤0.01% |
7,131
+205
| +3% | +$38.7K |
|
|
MNRL
509
DELISTED
Brigham Minerals, Inc. Class A Common Stock
MNRL
| $1.39M | ﹤0.01% |
72,731
+21,274
| +41% | +$409K |
|
510
Papa John's
PZZA
$811M
| $1.39M | ﹤0.01% |
10,968
+1,151
| +12% | +$139K |
|
|
ONC
511
BeOne Medicines Ltd
ONC
$36.7B
| $1.38M | ﹤0.01% |
3,799
-135
| -3% | -$44.1K |
|
512
iShares MSCI ACWI ETF
ACWI
$33.3B
| $1.34M | ﹤0.01% |
13,381
+690
| +5% | +$70.8K |
|
513
Citigroup
C
$224B
| $1.33M | ﹤0.01% |
18,991
+6,436
| +51% | +$450K |
|
514
Zimmer Biomet
ZBH
$18.8B
| $1.32M | ﹤0.01% |
9,267
-14
| -0.2% | -$2.06K |
|
515
Northern Trust
NTRS
$33.7B
| $1.28M | ﹤0.01% |
11,898
+906
| +8% | +$103K |
|
516
Clorox
CLX
$12.8B
| $1.28M | ﹤0.01% |
7,707
+1,068
| +16% | +$184K |
|
517
Invesco China Technology ETF
CQQQ
$3.17B
| $1.27M | ﹤0.01% |
19,313
-682
| -3% | -$48.8K |
|
|
NPTN
518
DELISTED
NEOPHOTONICS CORP
NPTN
| $1.26M | ﹤0.01% |
144,341
+45,132
| +45% | +$411K |
|
519
Valero Energy
VLO
$87.2B
| $1.25M | ﹤0.01% |
17,759
-1,175
| -6% | -$78.2K |
|
520
AnaptysBio
ANAB
$1.62B
| $1.25M | ﹤0.01% |
+46,019
| New | +$1.17M |
|
521
Pacific Biosciences
PACB
$363M
| $1.25M | ﹤0.01% |
48,849
+13,437
| +38% | +$398K |
|
522
iShares MSCI Switzerland ETF
EWL
$2.21B
| $1.25M | ﹤0.01% |
26,741
+1,101
| +4% | +$54.7K |
|
523
iShares Core S&P 500 ETF
IVV
$897B
| $1.24M | ﹤0.01% |
2,878
-556
| -16% | -$246K |
|
524
State Street Technology Select Sector SPDR ETF
XLK
$122B
| $1.23M | ﹤0.01% |
16,476
+2,624
| +19% | +$202K |
|
525
Columbia Banking Systems
COLB
$8.78B
| $1.23M | ﹤0.01% |
32,350
+4,297
| +15% | +$153K |
|
Similar funds
Ken Fisher's Q3 2021 Portfolio in Review
As of Q3 2021, Ken Fisher held 1,103 positions worth $161B, up 1.1% from $159B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Ken Fisher's Q3 2021 filing shows 93 new, 444 increased, 375 reduced and 75 closed positions. Its largest new stake was Biohaven Pharmaceutical Holding Company Ltd.: 267,976 shares worth $37.2M. The largest sale was Visa, an estimated $1.24B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 26% a quarter earlier, followed by Financials and Healthcare.
- Ken Fisher's largest Q3 2021 buy was Biohaven Pharmaceutical Holding Company Ltd.: 267,976 shares worth $37.2M.
- Ken Fisher added most to Meta Platforms (Facebook) in Q3 2021, an estimated $951M increase.
- Ken Fisher's biggest Q3 2021 reduction was Visa, cutting an estimated $1.24B.
- Ken Fisher fully exited Stamps.com, Inc. in Q3 2021, selling an estimated $111M.
- Ken Fisher's ten largest holdings make up 31% of its $161B portfolio in Q3 2021.
- Ken Fisher opened 93 new positions and closed 75 in Q3 2021.
- Ken Fisher's portfolio value rose 1.1% quarter-over-quarter to $161B.
Based on Fisher Asset Management's 13F filing for Q3 2021, filed 26 Oct 2021.